Recent data show that B cells and plasma cells located in tumours or in tumour-draining
lymph nodes can have important roles in shaping antitumour immune responses. In tumour …

Lung cancer is the leading cause of cancer-related death in the world. It is broadly divided
into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer (NSCLC, approx …

The present review is an update of the research and development efforts regarding the use
of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical …

The EarlyCDT-Lung test is a high-specificity blood-based autoantibody biomarker that could
contribute to predicting lung cancer risk. We report on the results of a phase IV biomarker …

Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

The United States Preventive Services Task Force recommends lung cancer screening with
low-dose computed tomography (LDCT) in adults of age 55 to 80 years who have a 30 pack …

Simple Summary During the development and progression of lung tumors, processes such
as necrosis and vascular invasion shed tumor cells or cellular components into various fluid …

Gastric cancer (GC)—a common tumor that affects humans worldwide—is highly malignant
with a poor prognosis. GC is frequently not diagnosed until a relatively advanced stage …

Introduction Low-dose computed tomography (LDCT) is used for screening for lung cancer
(LC) in high-risk patients in the United States. The definition of high risk and the impact of …

Lung cancer is associated with a heavy cancer-related burden in terms of patients' physical
and mental health worldwide. Two randomized controlled trials, the US-National Lung …